Blueprint Medicines (BPMC) USPTO patents

Utility

RET inhibitor for use in treating cancer having a RET alteration

16 Jan 24

Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.

Erica Evans Raab, Beni B. Wolf

Filed: 16 Jul 21

Utility

Compositions and Methods for Treating Kit- and Pdgfra-mediated Diseases

11 Jan 24

Thomas A. Dineen, Nicholas Lydon

Filed: 13 Oct 21

Utility

swc73v5c3djpsccg00flcpu3

28 Dec 23

The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof.

Gurulingappa Hallur, Naveena Madhyastha, Michael Rajesh Stephen, Bruce Roth, Anjali Pandey, Tracy Saxton

Filed: 30 Oct 21

Utility

esoqkbdd4gavics8n83y vvpyjv0zr3227knew5j28ervb4f

7 Dec 23

Thomas A. Dineen

Filed: 13 Oct 21

Utility

a15x911lm13p23qi4oe6r6f2je5wpzd56l7cnr7ee

28 Nov 23

Compounds and compositions useful for treating disorders related to mutant KIT are described herein.

Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang

Filed: 9 Nov 22

Utility

hdqnqfnqrnj o1kq6e091ixfp0tugx6ikj9z

12 Oct 23

Douglas Wilson, Neil Bifulco, JR., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky

Filed: 8 Feb 23

Utility

lddb6d27fz6ytv 73wshpbjo3wjdg

21 Sep 23

The compound cis)-N—((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4 methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide can be prepared as a free base in various crystalline solid forms, and in various salt forms each having one or more solid forms.

Joshua Waetzig, Gordon D. Wilkie, Lauren MacEachern, Kimberly Jean Miller

Filed: 28 May 21

Utility

zpots7yjrnml8lr0ugzildz4ise8h3 q8tpctkk2bu18fn7o

31 Aug 23

Joshua D. Waetzig, Gordon Wilkie

Filed: 8 Dec 22

Utility

v2cft2woo96 1l2uvy198hrasuibe1kns2p95mbyah

8 Aug 23

Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson

Filed: 8 Aug 22

Utility

i2xv07kaca83odk 979xocey1cc3wx5hngo44ddehlok

29 Jun 23

The present disclosure relates to pharmaceutical composition comprising 1) an amorphous solid dispersion comprising pralsetinib, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable hydrophilic polymer; and 2) an effervescent couple; and crystalline forms of pralsetinib and pralsetinib hydrochloride salt, which are useful as a RET selective inhibitors.

Joshua Waetzig, Gordon D. Wilkie, Debra L. Mazaik, Csanad M. Varga, Lia Rogal, Lauren MacEachern, Kimberly Jean Miller, Shellie Rigby-Singleton, Ian A. Barker, Robert J. Harris, Aimee J. Spenceley, Dipak Gordhan

Filed: 28 May 21

Utility

tsfosjy847s70hzykf67ril30wa16x44ov4yuozt0ia3jdqfjxcj1mzm2g8

25 May 23

Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky

Filed: 27 Jun 22

Utility

88yyykm9o2a0njmnhupnc60pg6g3v0yyf72

11 May 23

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof.

Jason D. Brubaker, Michael J. Burke, Joshua T. Close, Thomas A. Dineen, Joseph L. Kim, Chandrasekhar V. Miduturu, Emanuele Perola

Filed: 18 Oct 22

Utility

p8net9ug8apl6qvxxltuq20abvk0lx7c24ndkqmkbtaq

27 Apr 23

Compounds and compositions useful for treating disorders related to mutant KIT are described herein.

Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang

Filed: 9 Nov 22

Utility

9d92q8uykzf2gvk52xl3xdr9cyrupf

25 Apr 23

Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian Lewis Hodous, Joseph L. Kim, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin

Filed: 29 May 20

Utility

cf828c46g9nd5xqagn thr7g4

20 Apr 23

Brenton Mar

Filed: 8 Dec 22

Utility

8zotxtdf3q3 0hvex28u98

13 Apr 23

Jason D. Brubaker, Joshua T. Close, Thomas A. Dineen, Chandrasekhar V. Miduturu, Emanuele Perola

Filed: 13 Jul 22

Utility

rlzuxypx7jlx4rkpviouiat9ipr3cusgffjsnrh5j0d ejxw

23 Feb 23

John Emmerson Campbell, Thomas A. Dineen, Natasja Brooijmans, Jason D. Brubaker, Meredith Suzanne Eno, Joseph L. Kim, Aysegül Özen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Christopher De Savi

Filed: 29 Oct 21

Utility

iobkcyhpr 9w426sxi3vtr60co6m5188dfqhkd27tt

26 Jan 23

Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson

Filed: 8 Aug 22

Utility

vuuakgwu4c363daj66iklfjt1lyaen4nta3kumcrkqfj4svbj81ye3d3s7v

19 Jan 23

Omar Ahmad, John Emmerson Campbell, Thomas A. Dineen, Meredith Suzanne Eno, Dilinie Prasadhini Fernando

Filed: 9 Aug 22

Utility

6pqprieezrz5pi904zpqxr6e

27 Dec 22

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof.

Jason D. Brubaker, Chandrasekhar V. Miduturu, Michael J. Burke, Thomas A. Dineen, Joseph L. Kim, Joshua T. Close, Emanuele Perola

Filed: 14 Jan 21